LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER

Clinical trials for LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER explained in plain language.

Never miss a new study

Get alerted when new LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER trials appear

Sign up with your email to follow new studies for LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2 Completed 1

New gene therapy injection aims to boost prostate cancer radiation results

Disease control Recruiting now

This study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…

Matched conditions: LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER

Phase: PHASE2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 11:03 UTC

LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER

Get alerted when new LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER trials appear

New gene therapy injection aims to boost prostate cancer radiation results